VVTZ
2021-12-10
Abbie
[Cool]
AbbVie Shares Rise; Wells Fargo Lauds Growth Prospects<blockquote>艾伯维股价上涨；富国银行称赞增长前景</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
3
2
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":605357672,"tweetId":"605357672","gmtCreate":1639120203620,"gmtModify":1639120203620,"author":{"id":3582629808245810,"idStr":"3582629808245810","authorId":3582629808245810,"authorIdStr":"3582629808245810","name":"VVTZ","avatar":"https://static.tigerbbs.com/2a29e08a133febe21814a6f15264733d","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Abbie <span>[Cool] </span></p></body></html>","htmlText":"<html><head></head><body><p>Abbie <span>[Cool] </span></p></body></html>","text":"Abbie [Cool]","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/605357672","repostId":1101852117,"repostType":4,"repost":{"id":"1101852117","kind":"news","pubTimestamp":1639115859,"share":"https://www.laohu8.com/m/news/1101852117?lang=zh_CN&edition=full","pubTime":"2021-12-10 13:57","market":"us","language":"en","title":"AbbVie Shares Rise; Wells Fargo Lauds Growth Prospects<blockquote>艾伯维股价上涨；富国银行称赞增长前景</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1101852117","media":"TheStreet","summary":"AbbVie (ABBV) shares rose on Thursday after Wells Fargo analyst Mohit Bansal initiated coverage of t","content":"<p>AbbVie (<b>ABBV</b>) shares rose on Thursday after Wells Fargo analyst Mohit Bansal initiated coverage of the pharmaceutical titan at overweight on strong growth prospects.</p><p><blockquote>艾伯维(<b>ABBV</b>）周四，富国银行分析师Mohit Bansal在跑赢大盘首次报道这家制药巨头的强劲增长前景后，股价上涨。</blockquote></p><p> He also named it a top pick and has a $165 share-price target.</p><p><blockquote>他还将其列为首选，并将股价目标定为165美元。</blockquote></p><p> AbbVie recently traded at $123.54, up 1%. It has climbed 15% year to date, trailing the S&P 500’s 25% gain.</p><p><blockquote>艾伯维(AbbVie)近期交易价格为123.54美元，上涨1%。今年迄今为止，该股已上涨15%，落后于标普500 25%的涨幅。</blockquote></p><p> While many investors and analysts are focusing on the loss of exclusivity for AbbVie’s rheumatoid arthritis drug, Humira, the “strong growth prospects” of the company’s other treatments are “not yet fully appreciated,” Bansal wrote.</p><p><blockquote>班萨尔写道，虽然许多投资者和分析师都在关注艾伯维类风湿性关节炎药物修美乐（Humira）独家经营权的丧失，但该公司其他治疗方法的“强劲增长前景”“尚未得到充分认识”。</blockquote></p><p> “Our head-to-head analysis suggests that ABBV's ex-Humira business is bigger and growing faster than Eli Lilly (<b>LLY</b>) but is trading at 15 times estimated 2022 earnings.” That’s more than a 50% discount to Lilly, he said.</p><p><blockquote>“我们的面对面分析表明，ABBV的修美乐业务比礼来公司更大、增长更快（<b>LLY</b>）但其交易价格是2022年预期市盈率的15倍。”他说，这比礼来公司有50%以上的折扣。</blockquote></p><p> AbbVie has industry-leading 20% compound-annualized growth for earnings per share based on 2021-25 estimates for its non-Humira business, Bansal said.</p><p><blockquote>Bansal表示，根据对其非修美乐业务2021-25年的预测，艾伯维的每股收益复合年增长率为行业领先的20%。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AbbVie Shares Rise; Wells Fargo Lauds Growth Prospects<blockquote>艾伯维股价上涨；富国银行称赞增长前景</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAbbVie Shares Rise; Wells Fargo Lauds Growth Prospects<blockquote>艾伯维股价上涨；富国银行称赞增长前景</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">TheStreet</strong><span class=\"h-time small\">2021-12-10 13:57</span>\n</p>\n</h4>\n</header>\n<article>\n<p>AbbVie (<b>ABBV</b>) shares rose on Thursday after Wells Fargo analyst Mohit Bansal initiated coverage of the pharmaceutical titan at overweight on strong growth prospects.</p><p><blockquote>艾伯维(<b>ABBV</b>）周四，富国银行分析师Mohit Bansal在跑赢大盘首次报道这家制药巨头的强劲增长前景后，股价上涨。</blockquote></p><p> He also named it a top pick and has a $165 share-price target.</p><p><blockquote>他还将其列为首选，并将股价目标定为165美元。</blockquote></p><p> AbbVie recently traded at $123.54, up 1%. It has climbed 15% year to date, trailing the S&P 500’s 25% gain.</p><p><blockquote>艾伯维(AbbVie)近期交易价格为123.54美元，上涨1%。今年迄今为止，该股已上涨15%，落后于标普500 25%的涨幅。</blockquote></p><p> While many investors and analysts are focusing on the loss of exclusivity for AbbVie’s rheumatoid arthritis drug, Humira, the “strong growth prospects” of the company’s other treatments are “not yet fully appreciated,” Bansal wrote.</p><p><blockquote>班萨尔写道，虽然许多投资者和分析师都在关注艾伯维类风湿性关节炎药物修美乐（Humira）独家经营权的丧失，但该公司其他治疗方法的“强劲增长前景”“尚未得到充分认识”。</blockquote></p><p> “Our head-to-head analysis suggests that ABBV's ex-Humira business is bigger and growing faster than Eli Lilly (<b>LLY</b>) but is trading at 15 times estimated 2022 earnings.” That’s more than a 50% discount to Lilly, he said.</p><p><blockquote>“我们的面对面分析表明，ABBV的修美乐业务比礼来公司更大、增长更快（<b>LLY</b>）但其交易价格是2022年预期市盈率的15倍。”他说，这比礼来公司有50%以上的折扣。</blockquote></p><p> AbbVie has industry-leading 20% compound-annualized growth for earnings per share based on 2021-25 estimates for its non-Humira business, Bansal said.</p><p><blockquote>Bansal表示，根据对其非修美乐业务2021-25年的预测，艾伯维的每股收益复合年增长率为行业领先的20%。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.thestreet.com/investing/abbvie-initiated-overweight-rating-wells-fargo-on-growth-prospects\">TheStreet</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABBV":"艾伯维公司"},"source_url":"https://www.thestreet.com/investing/abbvie-initiated-overweight-rating-wells-fargo-on-growth-prospects","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1101852117","content_text":"AbbVie (ABBV) shares rose on Thursday after Wells Fargo analyst Mohit Bansal initiated coverage of the pharmaceutical titan at overweight on strong growth prospects.\nHe also named it a top pick and has a $165 share-price target.\nAbbVie recently traded at $123.54, up 1%. It has climbed 15% year to date, trailing the S&P 500’s 25% gain.\nWhile many investors and analysts are focusing on the loss of exclusivity for AbbVie’s rheumatoid arthritis drug, Humira, the “strong growth prospects” of the company’s other treatments are “not yet fully appreciated,” Bansal wrote.\n“Our head-to-head analysis suggests that ABBV's ex-Humira business is bigger and growing faster than Eli Lilly (LLY) but is trading at 15 times estimated 2022 earnings.” That’s more than a 50% discount to Lilly, he said.\nAbbVie has industry-leading 20% compound-annualized growth for earnings per share based on 2021-25 estimates for its non-Humira business, Bansal said.","news_type":1,"symbols_score_info":{"ABBV":0.9}},"isVote":1,"tweetType":1,"viewCount":1885,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":11,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/605357672"}
精彩评论